Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium

Allergan

Status: Completed

Conditions: Urinary Incontinence

Treatments: Biological: botulinum toxin Type A

Study type: Observational

Funder types: Industry

Identifiers

NCT02072928

MAF/AGN/NS/OAB/005

Details and patient eligibility

About

This study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical practice.

Enrollment: 55 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium
• Previous treatment with anticholinergic drugs ineffective
• Last BOTOX® treatment ≥18 months.

Exclusion criteria

• Diagnosis of urinary incontinence less than 9 months.
• No anticholinergic drug use in the last 9 months.

Trial design

55 participants in 1 patient group

BOTOX®

Description:

Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.

Treatment:

Biological: botulinum toxin Type A